Relaying what matters next.

In 2025, reasoning models went open weight and changed the unit economics of long‑horizon agents. Here is how lower costs, computer use, and better orchestration are shifting vendor moats from secret weights to operations, trust, and telemetry.

China’s Tianwen-2 aims to grab samples from Earth’s quasi-satellite Kamoʻoalewa, return them by 2027, then pivot to a main-belt comet. Here is why the two-target sprint could reshape planetary science, resources, and defense.

On December 3, 2025, Ethereum activates PeerDAS in the Fusaka upgrade, opening the door to bigger blob capacity and cheaper data for rollups. Here is how it could push L2 fees toward sub-cent and what teams should ship in the next 90 days.

Google Cloud made Ironwood TPUs generally available and upgraded Vertex AI Agent Builder. Together they cut latency and cost for real-world agents, setting up 2026 for sub-second loops and safer autonomy by default.

On September 10, 2025, Australia moved Ghost Shark from prototype to a fleet program of record, with first deployments slated for early 2026. Here is how long endurance autonomous submarines shift deterrence and kill chains across the Indo Pacific.

The FDA has cleared the first U.S. human trials of gene-edited pig kidneys. We unpack the 10 to 69 genomic edits, the new anti-rejection regimens, and the biosecure pig herds that could finally end the kidney shortage.

Two successful Starship flights in late 2025 set the stage. If SpaceX proves ship-to-ship propellant transfer in 2026, NASA timelines, Blue Origin’s plans, and science payload budgets all shift fast.

Arbitrum and the OP Stack just crossed a trust milestone: anyone can now challenge invalid rollup state on Ethereum. Here is what changes for withdrawals, bridges, exchanges, and builders in 2025.

Enterprise AI is pivoting from bigger models to verifiable runtime behavior. Use this vendor and standards map plus a 13 week build plan to harden agents without slowing delivery.

The James Webb Space Telescope has produced the first 3D weather map of an exoplanet, revealing a blazing hotspot, a cooler ring, and chemistry that changes with altitude and longitude on WASP-18b. Here is how eclipse mapping works and why it will reshape Roman and ELT target lists.

After August 2025 soldier demos and a new Sikorsky contract, the Army is moving Launched Effects from trials to fielding. Pods on Apaches and Black Hawks will push sensing, targeting, and strikes forward at standoff ranges, with Apache v6.5 and a federated Black Hawk package primed for 2026.

ESC 2025 data show low-dose colchicine can slow TET2-driven clonal growth, while new mega-cohort analyses pinpoint who is at risk. Here is why routine CHIP screening is near and how a 12–24 month rollout could work.

ESA’s Proba-3 has created artificial eclipses in orbit, exposing the Sun’s inner corona just as NASA’s Parker Solar Probe skimmed the atmosphere below. Together they are reshaping how we see coronal mass ejections and how we forecast space weather.

A once-in-a-generation visitor triggered a solar-system-wide observing sprint. From Mars orbiters to a spacecraft near Jupiter, coordinated teams turned geometry into data and speed into science.

Babylon’s Q4 2025 launch turns one Bitcoin stake into security for many chains through multi-staking and a new EVM mainnet. We unpack how it works, what to build now, and the milestones to watch into early 2026.

MISO and SPP compliance approvals, PJM's first transition studies, and early PJM-Google automation signal a real thaw in the U.S. interconnection queue. Here is how fast-track windows, queue caps, and AI can pull viable projects to 2026 energization.

With Windows 11 and major IDEs shipping native MCP support, the Model Context Protocol is tipping toward default. Here is how to ship IDE-native multi-agent orchestration, governed enterprise connectors, and security patterns now.

Two signals in 2025 mark a new era in cholesterol care. AHA VESALIUS-CV shows PCSK9 inhibitors prevent first cardiovascular events, and early Heart-2 data for VERVE-102 suggests single-infusion, durable LDL reductions following Lilly’s Verve acquisition.